HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $45 to $57.
HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $45 to $57.